The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | 5-year update of ELEVATE CLL TN
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, gives an update on the ELEVATE CLL TN study comparing the efficacy of obinutuzumab plus chlorambucil vs acalabrutinib plus obinutuzumab vs acalabrutinib monotherapy in patients with newly diagnosed chronic lymphocytic leukemia (CLL; NCT02475681). After five years, the study reported that patients treated with acalabrutinib plus obinutuzumab had a better progression-free survival (PFS) than patients treated with acalabrutinib monotherapy. In addition, the study reported a tolerable safety profile for patients treated with acalabrutinib plus obinutuzumab and acalabrutinib monotherapy, thereby supporting the use of these drugs as a standard of care (SOC) in newly diagnosed CLL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
